Oridonin Dose-Dependently Modulates the Cell Senescence and Apoptosis of Gastric Cancer Cells

Wang, Yiping; Lv, Hang; Dai, Chen; Wang, Xi; Yin, Yifei; Chen, Zhe

doi:10.1155/2021/5023536

Cited by 9 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, nding effective drug for the treatment of glioma is extraordinarily important. As a active diterpenoid and the main active factor of Rabdosia rubescens, ORI could inhibit multiple cancers include small cell lung cancer and gastric cancer [12,13]. However, the understanding about anti-glioma effect of ORI is limited.…”

Section: Discussionmentioning

confidence: 99%

Oridonin suppresses the growth of glioblastoma cells via inhibiting Hippo/YAP axis

wang

Zhang

Jiang

et al. 2022

Preprint

View full text Add to dashboard Cite

Glioma is a brain tumor that originated from brain or spine glial cells. Despite utilizing alternative treatments, the overall survival remains poor. Oridonin (ORI) is purified from the Chinese herb Rabdosia rubescens which exhibited anti-cancer effects on human tumorigenesis. The aim of this study was to investigate the effect of ORI on U87MG glioblastoma cells and whether Hippo/YAP-related signaling pathway was involved in. Here, we found that ORI inhibited cell proliferation and promoted cell apoptosis in a dose-dependent manner in U87MG cells. Moreover, ORI inhibited Bcl-2, YAP, c-Myc protein expression but increased Bax, caspase-3, p-YAP protein expression. Furthermore, these anti-cancer effects of ORI were also confirmed in a mouse model bearing glioma. Further study suggested that the YAP inhibitor Verteporfin (VP) showed the similar effect of ORI, but ORI reversed the effect of over-expression of YAP. Collectively, Oridonin suppressed glioblastoma oncogenesis via the Hippo/YAP signaling pathway and could be a potential therapeutic target in the treatment of glioblastoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Oridonin suppresses the growth of glioblastoma cells via inhibiting Hippo/YAP axis

wang

Zhang

Jiang

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…proteins (Gao et al, 2014). The anticancer influence of ORI is dosageand time-dependent pattern (Wang et al, 2021).…”

Section: Gastric Cancermentioning

confidence: 99%

“…It also induces G2/M‐phase cell cycle arrest by decreasing the expression of cyclinB1 and CDK1 proteins (Gao et al., 2014 ). The anticancer influence of ORI is dosage‐ and time‐dependent pattern (Wang et al., 2021 ).…”

Section: Ori Activity In Different Cancers In Vitro Studiesmentioning

confidence: 99%

Oridonin from Rabdosia rubescens: An emerging potential in cancer therapy – A comprehensive review

Ali,

Khan,

Ali

et al. 2024

Food Science & Nutrition

View full text Add to dashboard Cite

Cancer incidences are rising each year. In 2020, approximately 20 million new cancer cases and 10 million cancer‐related deaths were recorded. The World Health Organization (WHO) predicts that by 2024 the incidence of cancer will increase to 30.2 million individuals annually. Considering the invasive characteristics of its diagnostic procedures and therapeutic methods side effects, scientists are searching for different solutions, including using plant‐derived bioactive compounds, that could reduce the probability of cancer occurrence and make its treatment more comfortable. In this regard, oridonin (ORI), an ent‐kaurane diterpenoid, naturally found in the leaves of Rabdosia rubescens species, has been found to have antitumor, antiangiogenesis, antiasthmatic, antiinflammatory, and apoptosis induction properties. Extensive research has been performed on ORI to find various mechanisms involved in its anticancer activities. This review article provides an overview of ORI's effectiveness on murine and human cancer populations from 1976 to 2022 and provides insight into the future application of ORI in different cancer therapies.

show abstract

“…Oridonin has previously been investigated for its therapeutic effects on the following types of caners: colon, 2 , 3 , 6 , 10 , 11 breast, 12 , 13 pancreatic, 14 , 15 lung, 16 , 17 , 18 gallbladder, 19 prostate, 20 ovarian, 21 oesophageal, 22 oral, 23 , 24 bladder, 25 liver 26 and other cancers. It has been reported that the inhibitory effect of oridonin on proliferation of gastric cancer is mainly related to inducing apoptosis and promoting autophagy, 27 , 28 , 29 without further in‐depth discussions. Our previous study found that oridonin can block the G 2 /M phase of gastric cancer cells 30 and induce apoptosis 31 by affecting the expression of cyclinD1/CDK4 and cyclinA/CDK2 proteins.…”

Section: Introductionmentioning

confidence: 99%

Oridonin suppresses gastric cancer SGC‐7901 cell proliferation by targeting the TNF‐alpha/androgen receptor/TGF‐beta signalling pathway axis

Gao

Tan

2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF‐alpha/Androgen receptor/TGF‐beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC‐7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF‐α/Androgen receptor/TGF‐β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF‐α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF‐β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC‐7901 cells by regulating the TNF‐α /AR /TGF‐β signalling pathway axis.

show abstract

Oridonin Dose-Dependently Modulates the Cell Senescence and Apoptosis of Gastric Cancer Cells

Cited by 9 publications

References 45 publications

Oridonin suppresses the growth of glioblastoma cells via inhibiting Hippo/YAP axis

Oridonin suppresses the growth of glioblastoma cells via inhibiting Hippo/YAP axis

Oridonin from Rabdosia rubescens: An emerging potential in cancer therapy – A comprehensive review

Oridonin suppresses gastric cancer SGC‐7901 cell proliferation by targeting the TNF‐alpha/androgen receptor/TGF‐beta signalling pathway axis

Contact Info

Product

Resources

About